Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular hemolysis. Pegcetacoplan, an inhibitor of C3, prevents extravascular hemolysis. After 16 weeks of treatment, hemoglobin increased nearly 4 g...
Uloženo v:
| Vydáno v: | The New England journal of medicine Ročník 384; číslo 11; s. 1028 - 1037 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Massachusetts Medical Society
18.03.2021
|
| Témata: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular hemolysis. Pegcetacoplan, an inhibitor of C3, prevents extravascular hemolysis. After 16 weeks of treatment, hemoglobin increased nearly 4 g per deciliter in 41 patients treated with pegcetacoplan, and 85% no longer needed transfusion. |
|---|---|
| AbstractList | Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular hemolysis. Pegcetacoplan, an inhibitor of C3, prevents extravascular hemolysis. After 16 weeks of treatment, hemoglobin increased nearly 4 g per deciliter in 41 patients treated with pegcetacoplan, and 85% no longer needed transfusion. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis.BACKGROUNDParoxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis.We conducted a phase 3 open-label, controlled trial to assess the efficacy and safety of pegcetacoplan as compared with eculizumab in adults with PNH and hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After a 4-week run-in phase in which all patients received pegcetacoplan plus eculizumab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy (41 patients) or intravenous eculizumab (39 patients). The primary end point was the mean change in hemoglobin level from baseline to week 16. Additional clinical and hematologic markers of hemolysis and safety were assessed.METHODSWe conducted a phase 3 open-label, controlled trial to assess the efficacy and safety of pegcetacoplan as compared with eculizumab in adults with PNH and hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After a 4-week run-in phase in which all patients received pegcetacoplan plus eculizumab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy (41 patients) or intravenous eculizumab (39 patients). The primary end point was the mean change in hemoglobin level from baseline to week 16. Additional clinical and hematologic markers of hemolysis and safety were assessed.Pegcetacoplan was superior to eculizumab with respect to the change in hemoglobin level from baseline to week 16, with an adjusted (least squares) mean difference of 3.84 g per deciliter (P<0.001). A total of 35 patients (85%) receiving pegcetacoplan as compared with 6 patients (15%) receiving eculizumab no longer required transfusions. Noninferiority of pegcetacoplan to eculizumab was shown for the change in absolute reticulocyte count but not for the change in lactate dehydrogenase level. Functional Assessment of Chronic Illness Therapy-Fatigue scores improved from baseline in the pegcetacoplan group. The most common adverse events that occurred during treatment in the pegcetacoplan and eculizumab groups were injection site reactions (37% vs. 3%), diarrhea (22% vs. 3%), breakthrough hemolysis (10% vs. 23%), headache (7% vs. 23%), and fatigue (5% vs. 15%). There were no cases of meningitis in either group.RESULTSPegcetacoplan was superior to eculizumab with respect to the change in hemoglobin level from baseline to week 16, with an adjusted (least squares) mean difference of 3.84 g per deciliter (P<0.001). A total of 35 patients (85%) receiving pegcetacoplan as compared with 6 patients (15%) receiving eculizumab no longer required transfusions. Noninferiority of pegcetacoplan to eculizumab was shown for the change in absolute reticulocyte count but not for the change in lactate dehydrogenase level. Functional Assessment of Chronic Illness Therapy-Fatigue scores improved from baseline in the pegcetacoplan group. The most common adverse events that occurred during treatment in the pegcetacoplan and eculizumab groups were injection site reactions (37% vs. 3%), diarrhea (22% vs. 3%), breakthrough hemolysis (10% vs. 23%), headache (7% vs. 23%), and fatigue (5% vs. 15%). There were no cases of meningitis in either group.Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.).CONCLUSIONSPegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis. We conducted a phase 3 open-label, controlled trial to assess the efficacy and safety of pegcetacoplan as compared with eculizumab in adults with PNH and hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After a 4-week run-in phase in which all patients received pegcetacoplan plus eculizumab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy (41 patients) or intravenous eculizumab (39 patients). The primary end point was the mean change in hemoglobin level from baseline to week 16. Additional clinical and hematologic markers of hemolysis and safety were assessed. Pegcetacoplan was superior to eculizumab with respect to the change in hemoglobin level from baseline to week 16, with an adjusted (least squares) mean difference of 3.84 g per deciliter (P<0.001). A total of 35 patients (85%) receiving pegcetacoplan as compared with 6 patients (15%) receiving eculizumab no longer required transfusions. Noninferiority of pegcetacoplan to eculizumab was shown for the change in absolute reticulocyte count but not for the change in lactate dehydrogenase level. Functional Assessment of Chronic Illness Therapy-Fatigue scores improved from baseline in the pegcetacoplan group. The most common adverse events that occurred during treatment in the pegcetacoplan and eculizumab groups were injection site reactions (37% vs. 3%), diarrhea (22% vs. 3%), breakthrough hemolysis (10% vs. 23%), headache (7% vs. 23%), and fatigue (5% vs. 15%). There were no cases of meningitis in either group. Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.). BackgroundParoxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis.MethodsWe conducted a phase 3 open-label, controlled trial to assess the efficacy and safety of pegcetacoplan as compared with eculizumab in adults with PNH and hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After a 4-week run-in phase in which all patients received pegcetacoplan plus eculizumab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy (41 patients) or intravenous eculizumab (39 patients). The primary end point was the mean change in hemoglobin level from baseline to week 16. Additional clinical and hematologic markers of hemolysis and safety were assessed.ResultsPegcetacoplan was superior to eculizumab with respect to the change in hemoglobin level from baseline to week 16, with an adjusted (least squares) mean difference of 3.84 g per deciliter (P<0.001). A total of 35 patients (85%) receiving pegcetacoplan as compared with 6 patients (15%) receiving eculizumab no longer required transfusions. Noninferiority of pegcetacoplan to eculizumab was shown for the change in absolute reticulocyte count but not for the change in lactate dehydrogenase level. Functional Assessment of Chronic Illness Therapy–Fatigue scores improved from baseline in the pegcetacoplan group. The most common adverse events that occurred during treatment in the pegcetacoplan and eculizumab groups were injection site reactions (37% vs. 3%), diarrhea (22% vs. 3%), breakthrough hemolysis (10% vs. 23%), headache (7% vs. 23%), and fatigue (5% vs. 15%). There were no cases of meningitis in either group.ConclusionsPegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.) |
| Author | Kiladjian, Jean-Jacques Höchsmann, Britta Hamdani, Mohamed Szer, Jeff Usuki, Kensuke Risitano, Antonio Panse, Jens Röth, Alexander Weitz, Ilene Nishimori, Hisakazu Tan, Lisa Deschatelets, Pascal Griffin, Morag Ajayi, Temitayo Hillmen, Peter Grossi, Federico de Castro, Carlos Francois, Cedric de la Tour, Régis Peffault |
| Author_xml | – sequence: 1 givenname: Peter surname: Hillmen fullname: Hillmen, Peter organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 2 givenname: Jeff surname: Szer fullname: Szer, Jeff organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 3 givenname: Ilene surname: Weitz fullname: Weitz, Ilene organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 4 givenname: Alexander surname: Röth fullname: Röth, Alexander organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 5 givenname: Britta surname: Höchsmann fullname: Höchsmann, Britta organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 6 givenname: Jens surname: Panse fullname: Panse, Jens organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 7 givenname: Kensuke surname: Usuki fullname: Usuki, Kensuke organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 8 givenname: Morag surname: Griffin fullname: Griffin, Morag organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 9 givenname: Jean-Jacques surname: Kiladjian fullname: Kiladjian, Jean-Jacques organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 10 givenname: Carlos surname: de Castro fullname: de Castro, Carlos organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 11 givenname: Hisakazu surname: Nishimori fullname: Nishimori, Hisakazu organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 12 givenname: Lisa surname: Tan fullname: Tan, Lisa organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 13 givenname: Mohamed surname: Hamdani fullname: Hamdani, Mohamed organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 14 givenname: Pascal surname: Deschatelets fullname: Deschatelets, Pascal organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 15 givenname: Cedric surname: Francois fullname: Francois, Cedric organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 16 givenname: Federico surname: Grossi fullname: Grossi, Federico organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 17 givenname: Temitayo surname: Ajayi fullname: Ajayi, Temitayo organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 18 givenname: Antonio surname: Risitano fullname: Risitano, Antonio organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) – sequence: 19 givenname: Régis Peffault surname: de la Tour fullname: de la Tour, Régis Peffault organization: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen, Essen (A. Röth), the Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm (B.H.), and the Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen (J.P.) — all in Germany; the Department of Hematology, NTT Medical Center Tokyo, Tokyo (K.U.), and the Department of Hematology and Oncology, Okayama University Hospital, Okayama (H.N.) — both in Japan; Centre d’Investigations Cliniques (J.-J.K.) and the French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (R.P.T.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université de Paris, Paris; the Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC (C.C.); Apellis Pharmaceuticals, Waltham, MA (M.H., P.D., C.F., F.G., T.A.); and the Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy (A. Risitano) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33730455$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10c9LwzAUB_AgE_dDj16lIIKXapqf7VHG5pQ5d9BzSdN0ZDTNTFpx_vV2dgoOzOXl8HmPb_KGoFfZSgFwHsGbCFJ2u5g8PlmBIEogx0dgEFGMQ0Ig64EBhCgOCU9wHwy9X8P2RCQ5AX2MOYaE0gGYLtVKqlpIuylFFbwr5xsfTGRT6s_GiCzQVbAUzn5svRFlsLCyblzV3mbK2FVpM101TotTcFyI0quzfR2B1-nkZTwL58_3D-O7eSgJi-pQchLHbVaW04QSonieZSLDgkmOEyoRLghnUiDBEq5IjFjBaSQwVTGlKMlyPALX3dyNs2-N8nVqtJeqbLMr2_gU0fbJkHOMWnp5QNf2O3qnEI4Y3amLvWoyo_J047QRbpv-_FALwg5IZ713qvglEUx3G0j_bKD1-MBLXYta26p2Qpf_dl11Xcb4tFJr84_7Alf4kwo |
| CitedBy_id | crossref_primary_10_1016_j_cell_2025_03_039 crossref_primary_10_1002_pbc_31649 crossref_primary_10_1111_bjh_17963 crossref_primary_10_1182_blood_2024026299 crossref_primary_10_1038_s41584_023_00981_x crossref_primary_10_32818_reccmi_a10n2a18 crossref_primary_10_1002_ajh_27215 crossref_primary_10_1007_s12185_023_03698_5 crossref_primary_10_1002_eji_202350817 crossref_primary_10_1002_eji_202350816 crossref_primary_10_3390_biomedicines12122839 crossref_primary_10_1016_j_kint_2023_10_035 crossref_primary_10_1164_rccm_202112_2771OC crossref_primary_10_1080_17512433_2022_2109462 crossref_primary_10_3389_fonc_2023_1128994 crossref_primary_10_1007_s11239_025_03123_0 crossref_primary_10_1007_s12325_022_02111_7 crossref_primary_10_1007_s00277_025_06486_9 crossref_primary_10_1016_j_molimm_2022_08_010 crossref_primary_10_3390_ijms25168698 crossref_primary_10_1111_exd_14755 crossref_primary_10_3390_medicina60030379 crossref_primary_10_1056_NEJMc2106424 crossref_primary_10_1016_S2352_3026_22_00210_1 crossref_primary_10_3390_hematolrep15040060 crossref_primary_10_1016_j_smim_2022_101645 crossref_primary_10_1111_ejh_14422 crossref_primary_10_1007_s12325_022_02339_3 crossref_primary_10_1159_000540474 crossref_primary_10_3389_fimmu_2023_1297352 crossref_primary_10_1159_000540110 crossref_primary_10_3390_ijms26125902 crossref_primary_10_1007_s00281_022_00924_w crossref_primary_10_1007_s12325_023_02438_9 crossref_primary_10_1016_j_jbc_2024_105784 crossref_primary_10_3389_fphar_2021_770640 crossref_primary_10_3389_fonc_2022_947410 crossref_primary_10_1182_blood_2022017266 crossref_primary_10_3389_fimmu_2022_810993 crossref_primary_10_1002_ajh_27556 crossref_primary_10_1080_16078454_2025_2559333 crossref_primary_10_1056_NEJMc2404445 crossref_primary_10_3390_hematolrep16040065 crossref_primary_10_1111_imr_13137 crossref_primary_10_3389_fmed_2022_1097426 crossref_primary_10_1002_pbc_31070 crossref_primary_10_1053_j_seminhematol_2022_08_004 crossref_primary_10_3389_fimmu_2024_1307558 crossref_primary_10_3390_medicina59091612 crossref_primary_10_1002_ajh_27426 crossref_primary_10_3390_ijms252212104 crossref_primary_10_1007_s40265_025_02235_4 crossref_primary_10_1016_j_tracli_2021_08_352 crossref_primary_10_1097_HS9_0000000000000879 crossref_primary_10_1182_bloodadvances_2022006960 crossref_primary_10_1053_j_seminhematol_2022_01_001 crossref_primary_10_1177_20406207241307500 crossref_primary_10_1159_000540013 crossref_primary_10_3389_fimmu_2025_1529184 crossref_primary_10_3389_fimmu_2023_1226832 crossref_primary_10_1007_s40268_024_00463_9 crossref_primary_10_1007_s00277_024_05968_6 crossref_primary_10_1007_s00467_022_05755_3 crossref_primary_10_1056_NEJMra2201664 crossref_primary_10_1080_0886022X_2025_2525473 crossref_primary_10_1182_bloodadvances_2022009129 crossref_primary_10_1016_j_revmed_2022_09_004 crossref_primary_10_3390_jcm13061703 crossref_primary_10_1016_j_tips_2022_01_004 crossref_primary_10_1016_j_clicom_2022_11_002 crossref_primary_10_1007_s12325_025_03310_8 crossref_primary_10_1007_s40268_024_00500_7 crossref_primary_10_3389_fimmu_2025_1620996 crossref_primary_10_57264_cer_2023_0055 crossref_primary_10_1002_ajh_27242 crossref_primary_10_1016_j_imbio_2023_152413 crossref_primary_10_1038_s41467_022_33003_7 crossref_primary_10_1093_ndt_gfad079 crossref_primary_10_1002_ajh_70032 crossref_primary_10_1007_s00281_021_00896_3 crossref_primary_10_1172_JCI151092 crossref_primary_10_1016_j_drudis_2022_03_011 crossref_primary_10_1080_03007995_2024_2354533 crossref_primary_10_1002_ajh_26832 crossref_primary_10_1182_blood_2024027574 crossref_primary_10_1182_bloodadvances_2024015777 crossref_primary_10_2147_CEOR_S442906 crossref_primary_10_1007_s40265_022_01809_w crossref_primary_10_1172_JCI152973 crossref_primary_10_1007_s10238_025_01834_5 crossref_primary_10_1016_j_clim_2021_108785 crossref_primary_10_1080_07853890_2023_2274510 crossref_primary_10_3389_fimmu_2021_712572 crossref_primary_10_1007_s00508_024_02390_w crossref_primary_10_1080_14656566_2024_2404110 crossref_primary_10_1080_17474086_2025_2449864 crossref_primary_10_3390_pharmaceutics14051035 crossref_primary_10_1016_j_blre_2023_101041 crossref_primary_10_2147_JBM_S339660 crossref_primary_10_1038_s41409_025_02710_2 crossref_primary_10_1016_j_trsl_2022_02_001 crossref_primary_10_1080_17512433_2023_2209317 crossref_primary_10_1007_s10067_024_07067_3 crossref_primary_10_3390_ph18030293 crossref_primary_10_1080_1750743X_2024_2433410 crossref_primary_10_1007_s00277_021_04715_5 crossref_primary_10_1111_imr_13178 crossref_primary_10_1111_ijlh_14281 crossref_primary_10_1016_j_blre_2024_101210 crossref_primary_10_1007_s12325_023_02510_4 crossref_primary_10_3390_jcm14092889 crossref_primary_10_1007_s00467_023_06120_8 crossref_primary_10_1016_j_blre_2023_101158 crossref_primary_10_1182_blood_2024025176 crossref_primary_10_1002_eji_202350814 crossref_primary_10_1007_s40265_021_01560_8 crossref_primary_10_17650_1818_8346_2024_19_3_68_78 crossref_primary_10_57264_cer_2022_0178 crossref_primary_10_1111_imr_13164 crossref_primary_10_3390_jcm12082870 crossref_primary_10_1111_cts_70281 crossref_primary_10_1002_ajh_26882 crossref_primary_10_1007_s00277_024_05699_8 crossref_primary_10_1182_blood_2024023988 crossref_primary_10_1016_j_imbio_2021_152106 crossref_primary_10_3390_ijms232113333 crossref_primary_10_1038_s41409_023_01951_3 crossref_primary_10_1159_000537696 crossref_primary_10_1182_bloodadvances_2024012874 crossref_primary_10_1038_s41572_024_00566_2 crossref_primary_10_1002_jha2_748 crossref_primary_10_1016_j_ccm_2022_10_007 crossref_primary_10_1111_bjh_19070 crossref_primary_10_1007_s12325_023_02653_4 crossref_primary_10_1177_20503121231181267 crossref_primary_10_1007_s00277_024_05858_x crossref_primary_10_2147_JBM_S431493 crossref_primary_10_1016_S2352_3026_23_00315_0 crossref_primary_10_4049_jimmunol_2100031 crossref_primary_10_3390_jcm10204715 crossref_primary_10_1007_s00415_025_13225_7 crossref_primary_10_1007_s15004_024_0559_4 crossref_primary_10_1002_ajh_26998 crossref_primary_10_1016_j_rpth_2024_102435 crossref_primary_10_1016_j_jaut_2024_103216 crossref_primary_10_1007_s40267_025_01151_7 crossref_primary_10_1182_blood_2021014868 crossref_primary_10_1002_jha2_70095 crossref_primary_10_1016_j_clim_2023_109678 crossref_primary_10_1111_ejh_14026 crossref_primary_10_1111_ejh_13970 crossref_primary_10_1177_20406207231216080 crossref_primary_10_1093_ndt_gfae096 crossref_primary_10_1096_fj_202300571R crossref_primary_10_1016_S0140_6736_23_01524_6 crossref_primary_10_1097_MJT_0000000000001837 crossref_primary_10_1161_CIRCRESAHA_121_318225 crossref_primary_10_1038_s41392_024_02107_5 crossref_primary_10_1007_s00210_022_02250_2 crossref_primary_10_1016_j_intimp_2024_112583 crossref_primary_10_3390_hemato3040040 crossref_primary_10_1016_j_jbc_2025_108250 crossref_primary_10_1016_S2352_3026_22_00241_1 crossref_primary_10_1182_bloodadvances_2022009028 crossref_primary_10_3390_biom12030432 crossref_primary_10_1080_17474086_2024_2372333 crossref_primary_10_1080_17512433_2024_2403638 crossref_primary_10_1177_20406207221114673 crossref_primary_10_1080_17474086_2024_2440101 crossref_primary_10_21320_2500_2139_2025_18_3_197_208 crossref_primary_10_1007_s13311_022_01223_w crossref_primary_10_3389_fimmu_2023_1213920 crossref_primary_10_1056_NEJMoa2308695 crossref_primary_10_3389_fimmu_2021_830172 crossref_primary_10_1007_s00277_024_06088_x crossref_primary_10_1111_trf_16765 crossref_primary_10_1016_j_tips_2024_10_001 crossref_primary_10_1080_17474086_2022_2073215 crossref_primary_10_3389_fimmu_2022_811696 crossref_primary_10_2217_imt_2022_0085 crossref_primary_10_3201_eid3103_241182 crossref_primary_10_1007_s15004_021_8810_8 crossref_primary_10_1016_j_rpth_2024_102416 crossref_primary_10_1111_bjh_20024 crossref_primary_10_1111_bjh_20025 crossref_primary_10_1172_JCI178806 crossref_primary_10_3390_ijms26062504 crossref_primary_10_1002_jha2_714 crossref_primary_10_1177_20406207221091046 crossref_primary_10_3389_fimmu_2024_1521484 crossref_primary_10_3390_diseases13090298 crossref_primary_10_4049_jimmunol_2300242 crossref_primary_10_2147_JBM_S362220 crossref_primary_10_1093_ckj_sfad198 crossref_primary_10_1182_bloodadvances_2023011691 crossref_primary_10_23736_S0026_4806_25_09617_X crossref_primary_10_1038_s41409_022_01852_x crossref_primary_10_7759_cureus_81134 crossref_primary_10_1182_bloodadvances_2024012672 crossref_primary_10_1002_rth2_12781 crossref_primary_10_1111_ejh_13946 crossref_primary_10_1111_jcmm_17732 crossref_primary_10_1080_16078454_2024_2329030 crossref_primary_10_1007_s00277_023_05483_0 crossref_primary_10_1007_s40273_025_01472_5 crossref_primary_10_1080_14712598_2023_2209265 crossref_primary_10_2217_cer_2022_0076 crossref_primary_10_1016_j_msard_2025_106311 crossref_primary_10_3390_hematolrep15020027 crossref_primary_10_1002_hsr2_512 crossref_primary_10_1007_s00277_022_04887_8 crossref_primary_10_1007_s00277_022_04903_x crossref_primary_10_3390_cells12030449 crossref_primary_10_1111_bjh_17753 crossref_primary_10_1371_journal_pone_0306407 crossref_primary_10_1016_j_cmi_2021_06_030 crossref_primary_10_1007_s12325_024_02827_8 crossref_primary_10_1155_2022_1643674 crossref_primary_10_1111_ejh_13816 crossref_primary_10_1007_s41669_023_00408_z crossref_primary_10_1182_bloodadvances_2021006279 crossref_primary_10_3389_fimmu_2022_1060923 crossref_primary_10_1182_blood_2024027053 crossref_primary_10_1097_TP_0000000000004927 crossref_primary_10_3989_estgeogr_2024_1153 crossref_primary_10_1080_03007995_2021_1971182 crossref_primary_10_1080_16078454_2025_2450575 crossref_primary_10_1016_j_pharmr_2025_100079 crossref_primary_10_12890_2025_005721 crossref_primary_10_3390_ijms25179477 crossref_primary_10_1016_j_tmrv_2022_05_001 crossref_primary_10_17650_1818_8346_2024_19_1_83_91 crossref_primary_10_1111_ejh_14139 crossref_primary_10_1080_14728214_2022_2031973 crossref_primary_10_1182_blood_2021013169 crossref_primary_10_1182_blood_2022017860 crossref_primary_10_3389_fimmu_2021_751093 crossref_primary_10_1111_bjh_18274 crossref_primary_10_1111_ejh_13969 crossref_primary_10_31435_ijitss_3_47__2025_3842 crossref_primary_10_1111_ejh_14011 crossref_primary_10_1681_ASN_0000000000000192 crossref_primary_10_1016_j_smim_2022_101633 crossref_primary_10_1093_jleuko_qiae130 crossref_primary_10_1038_s41581_023_00766_1 crossref_primary_10_2147_JBM_S361863 crossref_primary_10_1007_s10238_022_00830_3 crossref_primary_10_2147_JIR_S322391 crossref_primary_10_3390_ijms25168591 crossref_primary_10_1182_blood_2021012860 crossref_primary_10_1002_jha2_632 crossref_primary_10_1016_j_blre_2022_101013 crossref_primary_10_2147_TCRM_S273360 crossref_primary_10_1002_cti2_1436 crossref_primary_10_1002_ajh_27502 crossref_primary_10_1016_j_smim_2022_101618 crossref_primary_10_1002_14651858_CD009300_pub3 crossref_primary_10_1007_s00134_024_07611_4 crossref_primary_10_1016_j_ekir_2025_04_061 crossref_primary_10_1016_j_mayocp_2025_06_005 crossref_primary_10_1016_j_revmed_2024_04_444 crossref_primary_10_3390_jcm12227185 crossref_primary_10_1093_ndt_gfae231 |
| Cites_doi | 10.1002/j.1460-2075.1994.tb06240.x 10.1056/NEJMc1010351 10.1002/cncr.10245 10.1038/nrdp.2017.28 10.1016/S0021-9258(18)42266-1 10.4049/jimmunol.1203200 10.1002/ajh.24278 10.1002/ajh.21757 10.4049/jimmunol.136.9.3390 10.1007/s00277-020-04052-z 10.1182/blood.V82.4.1192.1192 10.1038/nrd4657 10.1172/JCI114172 10.1056/NEJM199010253231707 10.1073/pnas.90.11.5272 10.1016/S1040-8428(99)00052-9 10.1007/978-1-4614-4118-2_10 10.1182/blood.V55.6.1040.1040 10.1111/j.1365-2141.2010.08096.x 10.3324/haematol.2009.007229 10.1111/bjh.15790 10.1182/blood-2011-02-333997 10.1182/blood-2008-11-189944 10.1016/j.ophtha.2019.07.011 10.1016/0092-8674(93)90250-T |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Massachusetts Medical Society. All rights reserved. Copyright © 2021 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2021 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2021 Massachusetts Medical Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1056/NEJMoa2029073 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central ProQuest Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database (ProQuest) Healthcare Administration Database (ProQuest) PML(ProQuest Medical Library) Psychology Database (ProQuest) Research Library Science Database (ProQuest) Biological Science Database (ProQuest) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: ProQuest Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 1037 |
| ExternalDocumentID | 33730455 10_1056_NEJMoa2029073 NJ202103183841108 |
| Genre | Original Article Clinical Trial, Phase III Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | - 0R 0WA 123 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 9M8 AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACPVT ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MQT MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADRHT ADUKH AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM AFOSN ALIPV CGR CUY CVF ECM EIF NPM UIG 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c461t-c74882026d59544e7dbbab3a6c7395c23f476ca2a697e4826f751a35e85529bd3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 293 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000630070600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Thu Oct 02 05:51:42 EDT 2025 Sat Nov 29 14:28:29 EST 2025 Thu Apr 03 07:07:22 EDT 2025 Sat Nov 29 07:51:29 EST 2025 Tue Nov 18 21:27:18 EST 2025 Tue Dec 21 14:38:50 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2021 Massachusetts Medical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c461t-c74882026d59544e7dbbab3a6c7395c23f476ca2a697e4826f751a35e85529bd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://ousar.lib.okayama-u.ac.jp/61532 |
| PMID | 33730455 |
| PQID | 2502231652 |
| PQPubID | 40644 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2502807732 proquest_journals_2502231652 pubmed_primary_33730455 crossref_primary_10_1056_NEJMoa2029073 crossref_citationtrail_10_1056_NEJMoa2029073 mms_nejm_10_1056_NEJMoa2029073 |
| PublicationCentury | 2000 |
| PublicationDate | 20210318 2021-03-18 |
| PublicationDateYYYYMMDD | 2021-03-18 |
| PublicationDate_xml | – month: 03 year: 2021 text: 20210318 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2021 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Hill, A, Rother, RP, Arnold, L (r017) 2010; 95 Cella, D, Lai, J-S, Chang, C-H, Peterman, A, Slavin, M (r021) 2002; 94 Ninomiya, H, Sims, PJ (r008) 1992; 267 Holguin, MH, Fredrick, LR, Bernshaw, NJ, Wilcox, LA, Parker, CJ (r011) 1989; 84 Risitano, AM, Notaro, R, Marando, L (r016) 2009; 113 Hill, A, Rother, RP, Wang, X (r014) 2010; 149 Boccuni, P, Del Vecchio, L, Di Noto, R, Rotoli, B (r006) 2000; 33 Hillmen, P, Bessler, M, Mason, PJ, Watkins, WM, Luzzatto, L (r004) 1993; 90 Kelly, RJ, Hill, A, Arnold, LM (r012) 2011; 117 Ricklin, D, Lambris, JD (r024) 2013; 190 Hillmen, P, Elebute, M, Kelly, R (r015) 2010; 85 Liao, DS, Grossi, FV, El Mehdi, D (r020) 2020; 127 Yamashina, M, Ueda, E, Kinoshita, T (r005) 1990; 323 Hill, A, DeZern, AE, Kinoshita, T, Brodsky, RA (r001) 2017; 3 Bessler, M, Mason, PJ, Hillmen, P (r002) 1994; 13 Risitano, AM, Notaro, R, Luzzatto, L, Hill, A, Kelly, R, Hillmen, P (r019) 2010; 363 Schrezenmeier, H, Röth, A, Araten, DJ (r022) 2020; 99 Takeda, J, Miyata, T, Kawagoe, K (r003) 1993; 73 Socié, G, Caby-Tosi, M-P, Marantz, JL (r025) 2019; 185 Kinoshita, T, Medof, ME, Nussenzweig, V (r007) 1986; 136 Loschi, M, Porcher, R, Barraco, F (r013) 2016; 91 Risitano, AM (r018) 2013; 735 Tumen, J, Kline, LB, Fay, JW (r009) 1980; 55 Morgan, BP, Harris, CL (r023) 2015; 14 Wiedmer, T, Hall, SE, Ortel, TL, Kane, WH, Rosse, WF, Sims, PJ (r010) 1993; 82 e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_6_2 e_1_3_4_5_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_23_2 e_1_3_4_20_2 e_1_3_4_21_2 e_1_3_4_26_2 e_1_3_4_24_2 e_1_3_4_25_2 e_1_3_4_11_2 e_1_3_4_12_2 e_1_3_4_10_2 e_1_3_4_15_2 e_1_3_4_16_2 e_1_3_4_13_2 e_1_3_4_14_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_18_2 34706184 - N Engl J Med. 2021 Oct 28;385(18):1725 38478008 - N Engl J Med. 2024 Mar 14;390(11):1060 34706182 - N Engl J Med. 2021 Oct 28;385(18):1723-1724 34706183 - N Engl J Med. 2021 Oct 28;385(18):1724-1725 |
| References_xml | – volume: 84 start-page: 7 year: 1989 end-page: 17 ident: r011 article-title: Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. publication-title: J Clin Invest – volume: 185 start-page: 297 year: 2019 end-page: 310 ident: r025 article-title: Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. publication-title: Br J Haematol – volume: 85 start-page: 553 year: 2010 end-page: 559 ident: r015 article-title: Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. publication-title: Am J Hematol – volume: 73 start-page: 703 year: 1993 end-page: 711 ident: r003 article-title: Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. publication-title: Cell – volume: 363 start-page: 2270 year: 2010 end-page: 2272 ident: r019 article-title: Paroxysmal nocturnal hemoglobinuria — hemolysis before and after eculizumab. publication-title: N Engl J Med – volume: 127 start-page: 186 year: 2020 end-page: 195 ident: r020 article-title: Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. publication-title: Ophthalmology – volume: 117 start-page: 6786 year: 2011 end-page: 6792 ident: r012 article-title: Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. publication-title: Blood – volume: 95 start-page: 567 year: 2010 end-page: 573 ident: r017 article-title: Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. publication-title: Haematologica – volume: 149 start-page: 414 year: 2010 end-page: 425 ident: r014 article-title: Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. publication-title: Br J Haematol – volume: 33 start-page: 25 year: 2000 end-page: 43 ident: r006 article-title: Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. publication-title: Crit Rev Oncol Hematol – volume: 99 start-page: 1505 year: 2020 end-page: 1514 ident: r022 article-title: Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. publication-title: Ann Hematol – volume: 113 start-page: 4094 year: 2009 end-page: 4100 ident: r016 article-title: Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. publication-title: Blood – volume: 55 start-page: 1040 year: 1980 end-page: 1046 ident: r009 article-title: Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cells. publication-title: Blood – volume: 94 start-page: 528 year: 2002 end-page: 538 ident: r021 article-title: Fatigue in cancer patients compared with fatigue in the general United States population. publication-title: Cancer – volume: 3 start-page: 17028 year: 2017 end-page: 17028 ident: r001 article-title: Paroxysmal nocturnal haemoglobinuria. publication-title: Nat Rev Dis Primers – volume: 136 start-page: 3390 year: 1986 end-page: 3395 ident: r007 article-title: Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes. publication-title: J Immunol – volume: 13 start-page: 110 year: 1994 end-page: 117 ident: r002 article-title: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. publication-title: EMBO J – volume: 90 start-page: 5272 year: 1993 end-page: 5276 ident: r004 article-title: Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. publication-title: Proc Natl Acad Sci U S A – volume: 91 start-page: 366 year: 2016 end-page: 370 ident: r013 article-title: Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. publication-title: Am J Hematol – volume: 14 start-page: 857 year: 2015 end-page: 877 ident: r023 article-title: Complement, a target for therapy in inflammatory and degenerative diseases. publication-title: Nat Rev Drug Discov – volume: 323 start-page: 1184 year: 1990 end-page: 1189 ident: r005 article-title: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. publication-title: N Engl J Med – volume: 735 start-page: 155 year: 2013 end-page: 172 ident: r018 article-title: Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. publication-title: Adv Exp Med Biol – volume: 267 start-page: 13675 year: 1992 end-page: 13680 ident: r008 article-title: The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the “b” domain of C9. publication-title: J Biol Chem – volume: 190 start-page: 3839 year: 2013 end-page: 3847 ident: r024 article-title: Complement in immune and inflammatory disorders: therapeutic interventions. publication-title: J Immunol – volume: 82 start-page: 1192 year: 1993 end-page: 1196 ident: r010 article-title: Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. publication-title: Blood – ident: e_1_3_4_3_2 doi: 10.1002/j.1460-2075.1994.tb06240.x – ident: e_1_3_4_20_2 doi: 10.1056/NEJMc1010351 – ident: e_1_3_4_22_2 doi: 10.1002/cncr.10245 – ident: e_1_3_4_2_2 doi: 10.1038/nrdp.2017.28 – ident: e_1_3_4_9_2 doi: 10.1016/S0021-9258(18)42266-1 – ident: e_1_3_4_25_2 doi: 10.4049/jimmunol.1203200 – ident: e_1_3_4_14_2 doi: 10.1002/ajh.24278 – ident: e_1_3_4_16_2 doi: 10.1002/ajh.21757 – ident: e_1_3_4_8_2 doi: 10.4049/jimmunol.136.9.3390 – ident: e_1_3_4_23_2 doi: 10.1007/s00277-020-04052-z – ident: e_1_3_4_11_2 doi: 10.1182/blood.V82.4.1192.1192 – ident: e_1_3_4_24_2 doi: 10.1038/nrd4657 – ident: e_1_3_4_12_2 doi: 10.1172/JCI114172 – ident: e_1_3_4_6_2 doi: 10.1056/NEJM199010253231707 – ident: e_1_3_4_5_2 doi: 10.1073/pnas.90.11.5272 – ident: e_1_3_4_7_2 doi: 10.1016/S1040-8428(99)00052-9 – ident: e_1_3_4_19_2 doi: 10.1007/978-1-4614-4118-2_10 – ident: e_1_3_4_10_2 doi: 10.1182/blood.V55.6.1040.1040 – ident: e_1_3_4_15_2 doi: 10.1111/j.1365-2141.2010.08096.x – ident: e_1_3_4_18_2 doi: 10.3324/haematol.2009.007229 – ident: e_1_3_4_26_2 doi: 10.1111/bjh.15790 – ident: e_1_3_4_13_2 doi: 10.1182/blood-2011-02-333997 – ident: e_1_3_4_17_2 doi: 10.1182/blood-2008-11-189944 – ident: e_1_3_4_21_2 doi: 10.1016/j.ophtha.2019.07.011 – ident: e_1_3_4_4_2 doi: 10.1016/0092-8674(93)90250-T – reference: 38478008 - N Engl J Med. 2024 Mar 14;390(11):1060 – reference: 34706183 - N Engl J Med. 2021 Oct 28;385(18):1724-1725 – reference: 34706182 - N Engl J Med. 2021 Oct 28;385(18):1723-1724 – reference: 34706184 - N Engl J Med. 2021 Oct 28;385(18):1725 |
| SSID | ssj0000149 |
| Score | 2.703991 |
| Snippet | Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular... Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls... BackgroundParoxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls... |
| SourceID | proquest pubmed crossref mms |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1028 |
| SubjectTerms | Adult Adverse events Aged Aged, 80 and over Anemia Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Blood diseases Chronic illnesses Complement C3 - antagonists & inhibitors Complement C5 - antagonists & inhibitors Complement component C3 Complement component C5 Complement Inactivating Agents - adverse effects Complement Inactivating Agents - therapeutic use Complement system Diarrhea Diarrhea - chemically induced Drug Therapy, Combination Erythrocyte Transfusion Fatigue Hemoglobin Hemoglobins - analysis Hemoglobinuria, Paroxysmal - blood Hemoglobinuria, Paroxysmal - drug therapy Hemoglobinuria, Paroxysmal - therapy Hemolysis Humans Injections, Subcutaneous - adverse effects Intravenous administration L-Lactate dehydrogenase Lactic acid Meningitis Middle Aged Monoclonal antibodies Paroxysmal nocturnal hemoglobinuria Patients Peptides - adverse effects Peptides - therapeutic use Peptides, Cyclic Thrombosis |
| SummonAdditionalLinks | – databaseName: New England Journal of Medicine Current dbid: DCD link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT-MwEB7x0ooLr12gvBQkxGkjaBy_jgiouFD1ABK3yHbtVVdNgkjDgV_PTJNWIFQhjlEmtjWPeMbfeAbgjJETy1IbB6NsnAZrYh0EPg4110EJw5Km2YTs99XTkx4swcXsLkzh_-dTAJ8smk6gZ93hL6g3fGkwVsdwji3DKk6iqVfDzfXNh3pRrb_bHhm1RTW_fP5pE1rO82qxfzndZ3qbP17hFmy0LmV01ejANiz5Ygd-3beg-W_oDfw_5yf463semyKiPIy6im5dPR691bmx0aiIBobSWaocx-mXhCrQiHc-L6lgyKioUU3_wGPv9uH6Lm7bJ8QuFd1J7CQaJ65GDLnmaerl0FpjmRGOwDmXsJBK4UxihJY-xTAjSN41jHvFeaLtkO3CSlEWfh8ilGhIXDAmKJVym1gkVsJLLbqWheA68HfGz8y1tcWpxcU4m2LcXGSfeNOB8zn5c1NUYxHhCQonI5YvIjiayS1rja_K0KtDp6creNKB0_lrNBvCQkzhy7qhUZdSMqTZa-Q9XwpjkvBjfvDd7IewnlCKC6X3qSNYmbzU_hjW3OtkVL2cTFXzHSEj3Ks priority: 102 providerName: Massachusetts Medical Society |
| Title | Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa2029073 https://www.ncbi.nlm.nih.gov/pubmed/33730455 https://www.proquest.com/docview/2502231652 https://www.proquest.com/docview/2502807732 |
| Volume | 384 |
| WOSCitedRecordID | wos000630070600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYhhAvjG_KRhUkxBPRljj-yBPaulZ7aYmqgfoW2Y49FTVJWRoe-Ou5S9zCHsoLLz_JyslKcmff2b_THSEfKAaxNNGhU1KHidMqTB2HYZGy1EmuaNw3mxCzmVws0sxfuDU-rXK7J3YbdVEbvCM_A1cNniziLP68_hFi1yhkV30LjQNyFKHvBnsW829_lY_y4a-_QfI1NsHnn2Gn-VrByR8Oh_SeTzooy2Z_uNm5ncnx_77wU_LEB5zBRW8hz8gDWz0nj6aeUn9BJpm9NXYDG-N6paoAszTaJhibdrX81ZZKB8sqyBQmuzQlzDOrkXPAGa9tWWM5kWXVghG_JF8n45vRdeibK4Qm4dEmNAKWLnw_L1jKksSKQmulqeIGqTsTU5cIblSseCpsAocQJ1ikKLOSsTjVBX1FDqu6sm9IAPp2sXFKOSkTpmMNwpJbkfJIU-fMgHza_t7c-Mrj2ABjlXcMOOP5PW0MyMed-LovubFPcAi6yiv7vdwncLpVTe6XZpP_0cuAvN89hkWFTImqbN32MvJcCAoyr3v1716FUoHsMnv778lPyOMY018w9U-eksPNXWvfkYfm52bZ3A07O0VciA4loBxFQ3J0OZ5lcxhdja4Ap-fzDm8Q42mHXzrMEEX2G9ll-AE |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB21BUEvfEO3lBIk4NSorB3byQEhBF1t1Xa1hyLtLdiOjRZtkqXZgOBH9Tcys0kWelhuPXCMMpok9vPM2PMyA_CSUxDLIxN6HZsw8kaHiZd4mSUi8bHUnDXNJtRoFE8myXgDLrt_YYhW2dnEpaHOSktn5IfoqtGT9aVg7-bfQuoaRdnVroVGA4sT9_MHbtmqt8cfcX5fMTY4Ov8wDNuuAqGNZH8RWoWYxS2_zEQiosipzBhtuJaWclaWcR8paTXTMlEuwujbK9HXXLhYCJaYjKPeTbiBdlwRhUxN1F_lqtpwuz2xamt6YoxxSJ3tS42Pxc0ov-IDN_O8Wh_eLt3c4O7_NkD34E4bUAfvmxVwHzZc8QBunbWUgYcwGLsv1i3Q8M9nugiIhVJXwZGtZ9Nfda5NMC2CsSYyT5WjnlFJORXSOHR5SeVSpkWNi_QRfLqWr3gMW0VZuB0IEM-eWa-1j-NIGGZQOJZOJbJvuPe2BwfddKa2raxODT5m6TLDL2R6ZfZ78HolPm9KiqwT3EdspIX7mq8T2OugkLamp0r_4KAHL1a30WhQJkgXrqwbmfiNUhxlnjRwW70K54qy52L338qfw-3h-dlpeno8OnkK24yoPkRzjPdga3FRu2dw035fTKuL_eUaCeDzdWPuNwjeSFQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BVW98KZdWkqQgBPRdu34kQNCiHbVqnS1hyL1FmzHRlttkqXZgOCn8es63jgLPSy3HjhGGU0S-_PM2PNlBuAV9UEsTXTslNRx4rSKU8fxMk9Z6iRXlLTNJsRoJC8u0vEa_O7-hfG0ys4mLgx1Xhl_Rt5HV42ebMAZ6btAixgfDt_PvsW-g5TPtHbtNFqInNqfP3D7Vr87OcS5fk3I8Oj843EcOgzEJuGDeWwE4he3_zxnKUsSK3KtlaaKG5-_MoS6RHCjiOKpsAlG4k6wgaLMSsZIqnOKetfhjkgY8XSys4Pzv0pXhdA7nF6F-p4Yb_R9l_tK4WNxY0pv-MP1oqhXh7oLlze8_z8P1gO4FwLt6EO7Mh7Cmi0fweZZoBI8huHYfjV2jg5hNlVl5NkpTR0dmWY6-dUUSkeTMhorT_KpC9QzqnyuxWs8tkXly6hMygYX7xP4fCtf8RQ2yqq0OxAhzh0xTiknZcI00SgsuRUpH2jqnOnB225qMxMqrvvGH9NskflnPLuBhB68WYrP2lIjqwT3ESdZaS-LVQJ7HSyyYJLq7A8mevByeRuNic8QqdJWTSsjD4SgKLPdQm_5KpQKn1Vnz_6t_AVsItSyTyej013YIp4B5NmPcg825leNfQ53zff5pL7aXyyXCL7cNuSuAZ7DUSQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pegcetacoplan+versus+Eculizumab+in+Paroxysmal+Nocturnal+Hemoglobinuria&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Hillmen%2C+Peter&rft.au=Szer%2C+Jeff&rft.au=Weitz%2C+Ilene&rft.au=R%C3%B6th%2C+Alexander&rft.date=2021-03-18&rft.eissn=1533-4406&rft.volume=384&rft.issue=11&rft.spage=1028&rft_id=info:doi/10.1056%2FNEJMoa2029073&rft_id=info%3Apmid%2F33730455&rft.externalDocID=33730455 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |